Key result
This review summarizes advances in the prediction and risk assessment of venous thromboembolism in lung cancer patients, focusing on early diagnosis, therapy, and mortality reduction.
Why the study?
Venous thromboembolism is a common complication in lung cancer affecting prognosis, prompting the development of clinical risk assessment models to identify high-risk patients.
This review summarizes current advances in clinical risk assessment models for predicting venous thromboembolism in lung cancer patients.
According to the most recent data from the National Cancer Center, venous thromboembolism (VTE) has unsurprisingly become one of the most common complications in lung cancer. VTE not only interferes with the equilibrium of the clotting system but it also affects tumor progression and prognosis. For the identification of high-risk patients, many clinical risk assessment models have been developed and validated based on the risk factors found in previous studies. In this review, we will summarize advances in prediction and risk assessment of VTE, with a focus on early diagnosis and therapy, reduction of mortality, and the burden of medical costs in lung cancer patients.
No takes yet. Share an insight, caveat, or question.
Di et al. (2021) conducted a review in Lung cancer-associated venous thromboembolism. Prediction and risk assessment models was evaluated. This review summarizes advances in the prediction and risk assessment of venous thromboembolism in lung cancer patients, focusing on early diagnosis, therapy, and mortality reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: